Ribociclib

About

Therapy type: Targeted therapy

Therapy strategy: CDK4/6 inhibition

Mappings

NCI Thesaurus: Ribociclib (ncit:C95701)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
EMA (1) FDA (2) ER positive, HER2-negative Invasive Breast Carcinoma Fulvestrant, Ribociclib
EMA (1) FDA (2) HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Ribociclib
EMA (1) FDA (2) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Ribociclib
FDA (1) ER positive, HER2-negative Invasive Breast Carcinoma Anastrozole, Ribociclib
FDA (1) HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Ribociclib
FDA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Ribociclib
EMA (1) FDA (1) ER positive, HER2-negative Invasive Breast Carcinoma Letrozole, Ribociclib
EMA (1) FDA (1) HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Ribociclib
EMA (1) FDA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Ribociclib
EMA (1) FDA (1) ER positive, HER2-negative Invasive Breast Carcinoma Anastrozole, Goserelin, Ribociclib
EMA (1) FDA (1) HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Goserelin, Ribociclib
EMA (1) FDA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Goserelin, Ribociclib
EMA (1) FDA (1) ER positive, HER2-negative Invasive Breast Carcinoma Goserelin, Letrozole, Ribociclib
EMA (1) FDA (1) HER2-negative, PR positive Invasive Breast Carcinoma Goserelin, Letrozole, Ribociclib
EMA (1) FDA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Goserelin, Letrozole, Ribociclib